Comment
doi: 10.1634/theoncologist.2008-0050.
Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
Affiliations
- PMID: 18448550
- DOI: 10.1634/theoncologist.2008-0050
Item in Clipboard
Comment
Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
Oncologist.
2008 Apr.
Free article
No abstract available
Comment on
-
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.Oncologist. 2008 Apr;13(4):361-9. doi: 10.1634/theoncologist.2007-0207. Oncologist. 2008. PMID: 18448549 Clinical Trial.
Similar articles
-
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.Cancer. 2008 Sep 15;113(6):1294-301. doi: 10.1002/cncr.23689. Cancer. 2008. PMID: 18661530
-
[The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].Acta Med Port. 2011 Jan-Feb;24(1):5-16. Epub 2011 Feb 28. Acta Med Port. 2011. PMID: 21672436 Portuguese.
-
HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.Anticancer Res. 2003 Mar-Apr;23(2A):1007-10. Anticancer Res. 2003. PMID: 12820339
-
Hidden HER-2/neu-positive breast cancer: how to maximize detection.IDrugs. 2009 Apr;12(4):238-42. IDrugs. 2009. PMID: 19350468 Review.
-
Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.Mod Pathol. 1999 Aug;12(8):827-34. Mod Pathol. 1999. PMID: 10463486 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
